Levina Elina, Ji Hao, Chen Mengqiang, Baig Mirza, Oliver David, Ohouo Patrice, Lim Chang-uk, Schools Garry, Carmack Steven, Ding Ye, Broude Eugenia V, Roninson Igor B, Buttyan Ralph, Shtutman Michael
Department of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, SC, USA.
Department of Biological Sciences, University of South Carolina, Columbia, SC, USA.
Oncotarget. 2015 May 30;6(15):13088-104. doi: 10.18632/oncotarget.3743.
Prostate cancer progression to castration refractory disease is associated with anomalous transcriptional activity of the androgen receptor (AR) in an androgen-depleted milieu. To identify novel gene products whose downregulation transactivates AR in prostate cancer cells, we performed a screen of enzymatically-generated shRNA lenti-libraries selecting for transduced LNCaP cells with elevated expression of a fluorescent reporter gene under the control of an AR-responsive promoter. The shRNAs present in selected populations were analyzed using high-throughput sequencing to identify target genes. Highly enriched gene targets were then validated with siRNAs against selected genes, testing first for increased expression of luciferase from an AR-responsive promoter and then for altered expression of endogenous androgen-regulated genes in LNCaP cells. We identified 20 human genes whose silencing affected the expression of exogenous and endogenous androgen-responsive genes in prostate cancer cells grown in androgen-depleted medium. Knockdown of four of these genes upregulated the expression of endogenous AR targets and siRNAs targeting two of these genes (IGSF8 and RTN1) enabled androgen-independent proliferation of androgen-dependent cells. The effects of IGSF8 appear to be mediated through its interaction with a tetraspanin protein, CD9, previously implicated in prostate cancer progression. Remarkably, homozygous deletions of IGSF8 are found almost exclusively in prostate cancers but not in other cancer types. Our study shows that androgen independence can be achieved through the inhibition of specific genes and reveals a novel set of genes that regulate AR signaling in prostate cancers.
前列腺癌进展为去势抵抗性疾病与雄激素受体(AR)在雄激素缺乏环境中的异常转录活性相关。为了鉴定其下调可在前列腺癌细胞中反式激活AR的新型基因产物,我们对酶促生成的shRNA慢病毒文库进行了筛选,选择在AR反应性启动子控制下荧光报告基因表达升高的转导LNCaP细胞。使用高通量测序分析选定群体中存在的shRNA,以鉴定靶基因。然后用针对选定基因的siRNA验证高度富集的基因靶标,首先测试AR反应性启动子的荧光素酶表达增加,然后测试LNCaP细胞中内源性雄激素调节基因的表达改变。我们鉴定了20个人类基因,其沉默影响在雄激素缺乏培养基中生长的前列腺癌细胞中外源性和内源性雄激素反应性基因的表达。其中四个基因的敲低上调了内源性AR靶标的表达,靶向其中两个基因(IGSF8和RTN1)的siRNA使雄激素依赖性细胞能够在不依赖雄激素的情况下增殖。IGSF8的作用似乎是通过其与一种四跨膜蛋白CD9的相互作用介导的,CD9先前与前列腺癌进展有关。值得注意的是,IGSF8的纯合缺失几乎只在前列腺癌中发现,而在其他癌症类型中未发现。我们的研究表明,通过抑制特定基因可以实现雄激素非依赖性,并揭示了一组调节前列腺癌中AR信号传导的新基因。